Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04464200 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04464200 · ClinicalTrials.gov record · last posted 2026-08-27

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

StatusActive, Not Recruiting
PhasePhase 1
Started2020-07-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they can test it in future participants to see if it is effective in treating their relapsed/refractory B-cell cell cancers. This study will also look at whether 19(T2)28z1xx CAR T cells work against participants' cancer.

Protocol amendment history 2 changes detected by DataLookout

2026-08-28
Primary completion pushed: 2026-07 → 2027-07
2026-08-28
Completion pushed: 2026-07 → 2027-07
Trial Details
NCT Number NCT04464200
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Takeda
Conditions Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma +1 more
Enrollment 30 participants
Start Date 2020-07-06
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-27